Teladoc Health, Inc. (NYSE:TDOC) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET

Company Participants

Chuck Divita - Chief Executive Officer
Mala Murthy - Chief Financial Officer
Michael Minchak - Head of Investor Relations

Conference Call Participants

Lisa Gill - J.P. Morgan
Stephanie Davis - Barclays
Jess Tassan - Piper Sandler
Jailendra Singh - Truist Securities
Richard Close - Cannacord Genuity
Elizabeth Anderson - Evercore ISI
Sarah James - Cantor Fitzgerald
Sean Dodge - RBC Capital Markets
Charles Rhyee - TD Cowen
Michael Cherny - Leerink Partners
Daniel Grosslight - Citi

Operator

Hello all, and welcome to Teladoc Health Second Quarter 2024 Earnings Call. My name is Lydia and I'll be your operator today. After the prepared remarks, there'll be an opportunity to ask questions. [Operator Instructions].

I'll now hand you over to Michael Minchak, Head of Investor Relations at Teladoc Health to begin. Please go ahead.

Michael Minchak

Thank you, and good afternoon. Today, after the market closed, we issued a press release announcing our second quarter 2024 financial results. This press release and the accompanying slide presentation are available in the investor relations section of the teladochealth.com website.

On this call to discuss the results are Chuck Divita, Chief Executive Officer; and Mala Murthy, Chief Financial Officer. During this call, we will also discuss our outlook and our prepared remarks will be followed by a question-and-answer session.

Please note that we will be discussing certain non-GAAP financial measures that we believe are important in evaluating Teladoc Health's performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliations thereof can be found in the press release that is posted on our website.

Also, please note that certain statements made during this call will be forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause the actual results for Teladoc Health to differ materially from those expressed or implied on this call. For additional information, please refer to our cautionary statement in our press release and our filings with the SEC, all of which are available on our website.

I would now like to turn the call over to Chuck.

Chuck Divita

Thanks, Mike, and good afternoon everyone. Let me start by saying how excited I am to have joined Teladoc Health and to lead the organization going forward. The company has many strengths to build upon and to drive higher levels of execution and performance.